ScanSource, Inc. (SCSC) Analysts See $0.79 EPS; BRIACELL THERAPEUTICS CORPORATION (BCTXF) Shorts Lowered By 80.36%

January 14, 2018 - By Adrian Mccoy

Analysts expect ScanSource, Inc. (NASDAQ:SCSC) to report $0.79 EPS on February, 6.They anticipate $0.04 EPS change or 5.33% from last quarter’s $0.75 EPS. SCSC’s profit would be $20.14 million giving it 11.28 P/E if the $0.79 EPS is correct. After having $0.76 EPS previously, ScanSource, Inc.’s analysts see 3.95% EPS growth. It closed at $35.65 lastly. It is down 0.87% since January 14, 2017 and is downtrending. It has underperformed by 17.57% the S&P500.

BRIACELL THERAPEUTICS CORPORATION (OTCMKTS:BCTXF) had a decrease of 80.36% in short interest. BCTXF’s SI was 7,600 shares in January as released by FINRA. Its down 80.36% from 38,700 shares previously. With 9,400 avg volume, 1 days are for BRIACELL THERAPEUTICS CORPORATION (OTCMKTS:BCTXF)’s short sellers to cover BCTXF’s short positions. The stock 0.26% or $0 during the last trading session, reaching $0.117. It is down 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 2 analysts covering ScanSource (NASDAQ:SCSC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ScanSource had 3 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, December 23 by Northcoast. Raymond James maintained the stock with “Outperform” rating in Tuesday, August 30 report. The rating was upgraded by Zacks to “Sell” on Wednesday, August 12.

Since September 18, 2017, it had 0 buys, and 3 insider sales for $2.58 million activity. $238,053 worth of stock was sold by BAUR MICHAEL L on Monday, October 9. Shares for $370,590 were sold by Reilly John Patrick.

Investors sentiment increased to 1.26 in Q3 2017. Its up 0.23, from 1.03 in 2017Q2. It improved, as 11 investors sold ScanSource, Inc. shares while 47 reduced holdings. 20 funds opened positions while 53 raised stakes. 23.93 million shares or 1.00% more from 23.70 million shares in 2017Q2 were reported. 64,300 were accumulated by Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Management. Voya Inv Mgmt Ltd Co stated it has 12,581 shares or 0% of all its holdings. State Street reported 676,544 shares. Denali Advisors Ltd Liability Corporation holds 0% or 33 shares. Serv Automobile Association invested in 133,692 shares. Glenmede Na accumulated 2,847 shares. Rhumbline Advisers holds 0.01% in ScanSource, Inc. (NASDAQ:SCSC) or 53,171 shares. Vanguard Grp Incorporated reported 2.39M shares. New York State Teachers Retirement owns 61,485 shares for 0.01% of their portfolio. Manufacturers Life Company The owns 18,861 shares. Principal Financial Group Inc Inc holds 0.01% or 197,117 shares. Alliancebernstein Ltd Partnership reported 34,321 shares. Pinebridge Lp has invested 0.04% in ScanSource, Inc. (NASDAQ:SCSC). Tci Wealth Inc invested in 0% or 22 shares. Arizona State Retirement Sys owns 13,182 shares or 0.01% of their US portfolio.

ScanSource, Inc. distributes technology products and solutions in North America, Latin America, and Europe. The company has market cap of $908.75 million. The companyÂ’s Worldwide Barcode, Networking & Security segment focuses on automatic identification and data capture , point-of-sale (POS), networking, electronic physical security, 3D printing, and other specialty technologies. It has a 15.57 P/E ratio. The Company’s AIDC and POS products are used to automate the collection, processing, and communication of information for commercial and industrial applications, such as retail sales, distribution, shipping, inventory control, materials handling, warehouse management, and health care applications; electronic physical security products, including identification, access control, video surveillance, intrusion-related, wireless, and networking infrastructure products; and 3D printing solutions to replace and complement traditional methods, as well as reduce the time and cost of designing new products.

BriaCell Therapeutics Corp., a biotechnology company, engages in the research and development of cancer immunotherapy technology in Canada. The company has market cap of $12.32 million. It is involved in developing BriaVax, a genetically engineered whole-cell vaccine that is in Phase I/IIa clinical trial to treat advanced breast cancer, as well as other cancers comprising prostate, ovarian, pancreas, lung, and bladder cancers; and BriaDx, a companion diagnostic test for BriaVax. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News